Navigation Links
Dr. Lowell S. Kabnick First to Use New VenaCure® 1470nm Laser

MORRISTOWN, N.J., June 9, 2011 /PRNewswire/ -- Dr. Lowell S. Kabnick, MD, RPhS, FACS, FACPh, Director of NYU Vein Center and internationally recognized authority and pioneer in the field of vascular surgery, is once again leading the way with breakthrough techniques, being the first in the country to use the new VenaCure® 1470nm laser to treat varicose veins. The new laser uses a lower power output compared with other lasers resulting in effective vein closure.

The VenaCure 1470nm laser's light energy is accurately delivered through the NeverTouch® gold-tip fiber, and is more readily absorbed by the water in the blood and endothelial lining than with other wavelengths. The specially engineered fiber tip has a low power density that maximizes effectiveness and minimizes postoperative pain and bruising. The VenaCure 1470nm lasers are manufactured in AngioDynamics' Cambridge, U.K., facility, and have received the CE mark and 510k clearance.

Ongoing research studies have found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period.

"The 1470nm laser enables us to be more efficient during a procedure, we are able to treat veins much more efficiently, which ultimately improves the patients procedure experience," stated Dr. Kabnick. "That translates into quicker recovery for patients."

About Lowell S. Kabnick, MD, RPhS, FACS, FACPh

Lowell S. Kabnick, MD, RPhS, FACS, FACPh, a New York University Surgeon with offices in Manhattan and Morristown, NJ and Director of NYU Vein Center, is a world-renowned surgeon-teacher whose patient-centered approach to vein care has enabled the creation and improvement of many of today's most advanced noninvasive vascular surgery techniques. Recognized by his peers as an international leader in the diagnosis and treatment of venous disease, Dr. Kabnick was the first vascular surgeon in the United States to perform the VNUS Closure™ (radiofrequency) procedure and the VenaCure EVLT® (laser) procedure - two FDA-approved breakthrough technologies for treating the underlying causes of many varicose vein problems. For more information, please visit

Lowell S. Kabnick, MD, RPhS, FACS, FACPh,

New Jersey:
95 Madison Ave
Suite 415
Morristown, NJ 07960
Phone: 973-538-2000

New York:
NYU Vein Center
530 First Avenue
Suite 6D
New York, NY 10016
Phone: 212-263-8346

SOURCE Lowell S. Kabnick
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
4. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Tainted Chinese Food Ingredients First Discovered in 2005
9. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Safe storage ... creativity of two inventors, one from Lakewood, New Jersey and the other from Bradley ... the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often ...
(Date:11/28/2015)... ... ... a.m. EST until 11:59 p.m. EST, customers will be racing the clock ... $80 or more to free gifts with purchases, there will be a new sale available ... for skin care and cosmetic needs, customers will save on already discounted prices. , Top ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the ... has not been an easy question to answer. Especially when the senior partners and ... don’t share the same discipline around working long hours. , In addition to ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... University of Toronto and the University of British Columbia suggested that laws requiring bicyclists ... The article explains that part of the reason for the controversial conclusion is that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at which ... age, more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions ... overworked. The forgotten part of this equation: 80 percent of medical care occurs ...
Breaking Medicine News(10 mins):